0.27
+0.2728(+136397.69%)
Currency In EUR
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
11
First IPO Date
August 06, 2008
| Name | Title | Pay | Year Born |
| Mr. Pascal Ghoson | Chief Executive Officer, Chief Financial Officer & Executive Director | 280,000 | N/A |
| Dr. Andy De Deene M.B.A., M.D. | Chief Development Officer | 0 | N/A |
| Mr. Philippe Barbeaux Ph.D. | Chief Scientific Officer | 0 | N/A |
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.